"Strong neutralizing antibody titers can offer protection in short-term viral challenge experiments, but when combined with potent CD8+ T cell responses against conserved regions of the viral genome, that protection may be more durable and less subject to immune escape, which is a key challenge facing first-generation mRNA vaccines today. The attractive properties of dose-sparing and expansive, more durable immunity underpin our plans to explore the broad protective and therapeutic utility of samRNA vaccines against COVID-19 and other viral pathogens.”
-- Results, which were previously pre-printed in bioRxiv, show Gritstone’s second-generation self-amplifying mRNA (samRNA) vaccine candidate drove broad neutralizing antibodies, T cell responses and offered protection against SARS-CoV-2 infection in
-- Results, which were previously pre-printed in bioRxiv, show Gritstone’s second-generation self-amplifying mRNA (samRNA) vaccine candidate drove broad neutralizing antibodies, T cell responses and offered protection against SARS-CoV-2 infection in
finance.yahoo.com
K
Self-amplifying mRNA (self-replicating) can reduce dosage from 100 to 10 mcg; potential cost / volume saving benefits.
Very promising overall treatment to advanced-tumor patients (good phase 1 results, randomized trials next and are currently underway and coming along nicely).
Shows promise for treatment of AIDS (treatment, NOT prevention - key difference to understand) and Covid variants, among other possible applications.
VERY PROMISING. Hence the recognition and funding ny the Gates Foundation and NIH.
Very informative explanation by Dr. Andrew Allan. A must watch.
Gritstone bio Inc President & CEO Dr. Andrew Allen joined Proactive to discuss the Emeryville, California-based biotechnology group's latest clinical progres...
Gritstone bio Inc President & CEO Dr. Andrew Allen joined Proactive to discuss the Emeryville, California-based biotechnology group's latest clinical progres...
www.youtube.com
C
Stock is in a recovery mode. Get back in before too late
M
Well, well, nice news today. Important to remember that it is advanced cancer, and the median survival was still 18 months compared to 7 months or so. That means that survival in patiens with cancer that is less advanced will likely benefit even more. Hugo news!
S
Better buy this stock now before it's 10 to 12 bucks in December and 20 dollars a year from now.
E
Do not trust this management.....
D
7-8 Months increased survival rate is impressive results. Important is concept is working which Modern also trying.
S
Up 20% & already at average daily volume first 30mins of trading day. Somethings looking good.
S
This is a load up for 2nd half stock.....limited downside but limitless upside..... I'll load and wait for xmas time.
c
Does this stock have ANY hope? I bought in around $11.00+ Granted only a handful of shares, but I expected good things and then buy on the way up. I’m glad I only tested the waters but it sure looks muddy!
E
Do not trust this management.....
E
Do not trust this management.....
E
Gritstone Earns 2022 Great Place to Work Certification™. But the bad company for investment.
v
Bullish even given the stock price. Much data in 2nd half may surprise and awe !
https://finance.yahoo.com/news/gritstone-announces-results-preclinical-study-120000550.html
Bullish / Strong Buy
Very promising overall treatment to advanced-tumor patients (good phase 1 results, randomized trials next and are currently underway and coming along nicely).
Shows promise for treatment of AIDS (treatment, NOT prevention - key difference to understand) and Covid variants, among other possible applications.
VERY PROMISING. Hence the recognition and funding ny the Gates Foundation and NIH.
Very informative explanation by Dr. Andrew Allan. A must watch.
Bullish / Strong Buy
https://youtu.be/2cf1cEXM4Rc
I bought in around $11.00+
Granted only a handful of shares, but I expected good things and then buy on the way up.
I’m glad I only tested the waters but it sure looks muddy!